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Summary
The tal-1 proto-oncogene encodes a helix-loop-helix DNAbinding protein that has been implicated
in the formation of T cell acute lymphoblastic leukemia (TALL). Patients with TALL harbor
structural rearrangements of tal-1 that result from either local DNA deletion or t(1;14)(p34;gll)
chromosome translocation. By analyzing t(1;14)(p34;gll) chromosomes from a series ofpatients,
we have now identified a discrete region of tal-1 wherein most of the translocation breakpoints
occur. Moreover, mapping of tal-1 genomic DNA revealed that coding exons are situated on
both sides of the t(1;14)(p34;gll) major breakpoint region. Hence, the translocated allele of tal-1
is truncated in a manner that reduces its amino acid coding potential.
T
he tal-1 gene was identified upon analysis of t(1;14)
(p34;gll), a chromosome translocation observed in the
malignant cells of patients with T cell acute lymphoblastic
leukemia (TALL)t (1-4). Although it is found in only 3%
of these patients, t(1;14)(p34;gll) has been implicated as a
causative factor of leukemogenesis based on its occurrence
in unrelated patients and its exclusive association with TALL
(5). The translocation generates a reciprocalexchange of genetic
material between chromosomes 1 and 14 with cytogenetic
breakage in chromosomal bands lp34 and 14gll. Conse-
quently, the tal-1 gene from chromosome 1 is transposed into
the TCR-ac/S chain locus at 14gll, whereupon its expres-
sion is presumably altered in a manner that promotes the for-
mation of TALL.
Two additional lines of evidence support the notion that
tal-1 is a protooncogene that potentially contributes to the
development of TALL. First, the tal-1 gene product is a
member of the helix-loop-helix (HLH) family of DNA
binding proteins (1, 6), several of which have been shown
to specifically recognize core sequences of eucaryotic tran-
scriptional enhancers (7-10). Although HLH proteins con-
trol diverse aspects of normal cell growth and differentiation,
three members of this family (i.e., c-m)c, lyl-1, and E2A) have
'Abbreviations used in this paper: HLH, helix-loop-helix; mbr, major
breakpoint region; TALL, T cell acute lymphoblastic leukemia.
also been implicated in human acute lymphoblastic leukemia
(11-13) . Second, despite the infrequency of t(1;14)(p34;gll)
translocation, we have recently shown that -25% of TALL
patients harbor a site-specific 90-kb deletion (taM) of the tal-1
gene that is apparently undetectable by cytogenetic analysis
(14). Therefore, structural alteration oftal-1, either by t(1;14)
(p34;gll) translocation or 0 deletion, represents the most
common genetic lesion associated with human TALL.
The mechanism by which translocated alleles of tal-1 are
activated in malignancy is not understood. To address this
issue, we have analyzed the structures of t(1;14)(p34;gll)chro-
mosome junctions from a series of TALL patients. In each
of five cases, the translocation breakpoint on chromosome
1 occurred within a discrete 1-kb region of the tal-1 locus.
Moreover, mapping of tal-1 genomic DNA revealed that
coding exonsare situated on both sides of the t(1;14)(p34;gll)
major breakpoint region (mbr). Hence, the translocated al-
lele of tal-1 is truncated in a manner that reduces its amino
acid coding potential.
Materials and Methods
The Patients.
￿
Clinical features of the pediatric TALL patients
(cases 1 and 2) and karyotypic studies of their leukemic cells have
already been described (5) . The adult TALL patient (case 0) was
a 42-yr-old male with marked hyperleukocytosis comprised ofleu-
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phoblasts revealed an abnormal karyotype : 46,XYdel(6)(g11q21),
t(1;14)(p34;g11). Leukemic cells analyzed in this report were de-
rived from peripheral blood obtained just before treatment . The
original designation ofthe t(1;14) translocation described a break-
point in thep32 band ofchromosome 1 (1) ; with improved karyo-
typic resolution ofadditional cases, wenowbelieve that the break-
point lies in the proximal portion of p34 rather than in p32 (5) .
DNA Analysis and Cloning.
￿
DNAs extracted from leukemic
specimens were analyzed by Southern hybridization with radiola-
beledDNA probes (15) . GenomicDNA libraries ofBamHI-digested
leukemic DNA were constructed in phage vector X2001, and re-
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striction fragments of recombinant XDNA were subcloned into
plasmidand M13 phage vectors (15) . Nucleotide sequence analyses
were performed onM13 single-stranded templatesby the chain ter-
minator method (16) .
Results and Discussion
In a recent cytogenetic study, the t(1;14)(p34;g11) trans-
location was observed in 5 of 168 children with TALL (5).
We previously characterized translocationjunctions fromtwo
ofthese patients (cases 4 and 5), and found that the chromo-
Figure 1 .
￿
The t(1;14)(p34 ;g11)junc-
tions ofpatients 0 and 2 . Southern anal-
ysis ofBamHl-digested DNAs hybrid-
izedwith probe B2EE-2.0 (A) or probe
R28EX-4.9 (B) . (Lanes C) Control
DNAfrom aB lymphoblastoid cell line;
(lanes 1, 2, and 0) leukemicDNAfrom
patients 1, 2, and 0, respectively. Sizes
of HindlllXDNA fragments are indi-
cated (in kilobases) to the left of each
autoradiogram . (C) Recombinant clones
XS andXSh were obtained from phage
libraries of leukemic DNAs from pa-
tients 2and 0, respectively.TheXS and
XSh maps are compared with those of
the germline tal-1 locus and the D6JS
region of a germline TCR-a/b chain
gene. Closed boxes represent chromo-
some 14 sequences, and open boxes
represent chromosome 1 sequences .
Sequences encoding the tal-1HLH do-
main are represented by a hatched box .
(D) Comparison of t(1;14)(p34;gll)
junction sequences from patients 2and
0with the germline sequence of chro-
mosome 1 . Uppercase letters represent
chromosome 1 sequence, and lowercase
letters represent chromosome 14 se-
quence (exixptingnucleotides generated
by random N-region insertion, which
are underlined). Coding sequences de-
rived from the TCR gene segments
Dbl, D62, and J61 are overlined with
arrows .some 1 breakpoints occurred 1 kb apart at positions Nil and
N12 kb, respectively, upstream of genomic sequences en-
coding the tal-1 HLH domain (see Fig. 1 C) (1). To deter-
mine whether this region represents acommon site ofchro-
mosome translocation, we have analyzed t(1;14)(p34;g11)
leukemic DNAs from an adult TALL patient (case 0) and
two additional pediatric patients (cases 1 and 2). As shown
in Fig. 1 A, patients 0 and 2 both exhibit a rearranged 12.2-
kb BamHI fragment upon Southern hybridization with the
tal-1 DNA probeB2EE-2.0. Moreover, rearranged fragments
of identical size were also detected in these patients by hy-
bridization with a DNA probe (R28EX-4.9) from theJS re-
gion of the TCR-a/8 chain gene (Fig. 1 B). Therefore, X
phage libraries ofBamHI-digested leukemic DNAs from pa-
tients 0 and 2 were constructed, and recombinant clones con-
taining the 12.2-kb fragments were isolated by simultaneous
screening with B2EE-2.0 and R28EX-4.9. Since the rearranged
12.2-kb fragments contain sequences from bothchromosome
1(B2EE-2.0) and chromosome 14 (R28EX-4.9), they are likely
to encompass the t(1;14)(p34;gll)junctions of patients 0 and
2. This was confirmed by restriction mapping and nucleo-
tide sequence analysis of the recombinant clones (XSh from
patient 0; XS from patient 2), which revealed that the rear-
ranged fragments are comprised oftal-1 sequencesjuxtaposed
with the TCR J81 gene segment (Fig. 1, C and D).
As illustrated in Fig. 1 A, the tal-1 probe B2EE-2.0 de-
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tects two rearranged BamHI fragments (14.1 and 4.3 kb) in
leukemic DNA from patient 1. To determine whether either
fragment represents a t(1;14)(p34;g11) junction, a X phage
library of BamHI-digested DNA from patient 1 was con-
structed and screened with the B2EE-2.0 probe. In this manner,
three hybridizing clones were obtained, each of which con-
tained the rearranged 14.1-kb fragment. Restriction mapping
and sequence analysis of one such clone (XA) revealed it to
be comprised of B2EE-2.0 sequences (chromosome 1) juxta-
posed with sequences from the CS region of the TCR-cx/S
chain gene (chromosome 14) (Fig. 2).
Two abnormal chromosomes, der(1) and der(14), are gener-
ated as a consequence of t(1;14)(p34;g11) translocation (5).
From the known orientation of the TCR-cx/S chain gene
on chromosome 14, we can deduce that the t(1;14)(p34;g11)
junctions of clones XS, XSh, and XA (Figs. 1 C and 2 A)
are derived from the der(1) chromosomes of patients 2, 0,
and 1, respectively. A genetic map of tal-1 is provided in Fig.
3, and the der(1) breakpoints from these patients are illus-
trated along with those previously determined for patients
4 and 5. The t(1;14)(p34;g11) breakage in patient 1 occurs
within sequences represented by the B2EE-2.0 probe; hence,
Southern analysis with this probe revealed two rearranged
fragments in digests ofpatient 1 leukemic DNA (Fig. 1 A),
one ofwhich corresponds to the der(1) junction (i.e., the 14.1-
kb BamHI fragment), while the other is likely to represent
chromosome 14
tttatttttatacagaaaattagccaggtgtggtggtgttIIgcacctgtggtcccagctactcg
i
to (patient I)
￿
;
TTAAAATAATCATCCCAGAGCGCAG
i
tcgtacgccgtgaggcacctgtggtcccagctactcg
i
chromosome 1
TTAAAATAATCATCCCAGAGCGCAGCAGTTTGTCCCTTTTGGCTCCTTTGGCGGGAGAACAA
Figure 2.
￿
Thet(1;14)(p34;g11)junction of
patient 1. (A) Recombinant cloneMwas ob-
tained from a phagelibrary of patient 1 leu-
kemicDNA. The aA map is compared with
thoseofthegermline tal-1locusandtheJ8-C8
region of the TCR-u/8 chain gene. Closed
boxes represent chromosome 14 DNA, and
open boxes representchromosome 1DNA.Se-
quences encoding the tal-1 HLH domain are
represented by a shaded box. (B) Comparison
ofthet(1;14) (p34;g11)junction sequence with
germline sequences from chromosomes 1 and
14. Uppercaseletters representchromosome 1
sequence,andlowercase lettersrepresent chro-
mosome 14 sequence (accepting nucleotides
generatedby random N-region insertion, which
are underlined).
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B H Bthe der(14) junction (i.e., the 4.3-kb BamHI fragment).
Southern hybridization with the tal-1 probe SUM (Fig. 3)
revealed DNA rearrangements corresponding to the der(14)
junctions in leukemic DNA from each of the five patients
(datanot shown). Hence, in these patients, the t(1;14)(p34;g11)
rearrangement is conservative with respect to chromosome
1; that is, the continuity of tal-1 was disrupted, but few, if
any, tal-1 sequences were lost as a consequence ofthe translo-
cation. In contrast, Southern analyses with probes located
upstream of the chromosome 14 breakpoints (e.g., EH-2.0;
Fig. 1 C) indicate that substantial portions of the TCR locus
were lost from the translocated alleles (data not shown), in
accord with previous studies of other chromosomes defects
involving the TCR-ct/6 chain gene (17).
As illustrated in Fig. 3, the five t(1;14)(p34;g11)breakpoints
described in our studies cluster within a 1-kb region located
-11 kb upstream of sequences encoding the tal-1 HLH do-
main. Recently, t(1;14)(p34;g11) translocations from two ad-
ditional patients were described at the molecular level(2-4).
Notably, t(1;14)(p34;g11) breakage in the TALL cell line Kd
also occurs within the same region of tal-1 that is disrupted
in patients 0, 1, 2, 4, and 5 (2). In contrast, the t(1;14)(p34;g11)
breakpoint of DU.528, a cell line derived from a rare stem
cell leukemia, lies within 3'-noncoding sequences (designated
SCL or td-5) of the tal-1 transcription unit (3, 4). In sum,
six of the seven t(1;14)(p34;g11) translocations characterized
A
B
axon II
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AGGGGCCGGGCCGCCGCCGCTCAGGACCGGGCCTCAAAATGGCCACACGCGTACCCCCGTAGCGGAAAAACGTGAGCATT
to datefeature breakage within what can be described as the
major breakpoint region (mbr) of tal-1.
Since t(1;14)(p34;g11) is observed in only 3% of TALL
patients (5), alteration oftal-1by chromosome translocation
is clearly an uncommon factor in the formation of TALL.
Nevertheless, we recently detected tumor-specific rearrange-
ment ofthe tal-1 gene in -25% ofTALL patients, including
those without apparent karyotypic lesions of chromosome
1 (14). Surprisingly, the tal-1 rearrangements observed in
different patients are nearly identical; that is, they all result
from a precise 90-kb deletion (designated talc) that arises in-
dependently in each patient by site-specific recombination (14).
It may be significant that the downstream endpoint of the
tall deletion occursjust 1 kb upstream of the tal-1 mbr (see
Fig. 3). Hence, tald deletion and t(1;14)(p34;g11) transloca-
tion are structurally analogous lesions in that both serve to
remove upstream sequences from the body of the tal-1 gene.
To understand the effect of t(1;14)(p34;g11) translocation
on tal-1 gene expression, it is necessary to localize the mbr
with respect to the tal-1 transcription unit. Although the
initiation site(s) of tal-1 transcription is not known, at least
two distinct mRNA species have been identified by cDNA
sequence analysis (1, 6). Both transcripts encode the tal-1 HLH
domain but differ from each other in their 5' sequences. To
determine the origin of these sequences, we examined tal-1
genomic DNA by Southern hybridization with oligonucle-
Figure 3.
￿
(A) Genetic map of the
tal-1 locus. The small arrows designate
the breakpoints of t(1;14)(p34;g11)
translocations from patients 0, 1, 2, 4,
and 5. The large arrow indicates the
downstream endpoint of the 90-kb tale
deletion. The hatched regions of the
tal-1 axons denote coding sequences, and
the open regions denote 3' noncoding
sequence. Restriction sites: B, BamHl;
G
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￿
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N
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E, EcoRl; H, Hindl1l. (B) Genomic
TTCCCTCCCACAGCGGGTTCTTTGGGGAGCCGGATGCCTTCCCTATGTTCACCACCAACAATCGAGTGAAGAGGAGACCT DNA sequences encompassing the
known upstream exons (la, lb, and 11)
of tat-1. RNA splice sites are indicated
with arrowheads.
axon rb
A S V T A E L P G D G R M V Q L S P P A L A A P A A
CCGCCTCGGTTACAGCGGAGCTGCCCGGCGACGGCCGCATGGTGCAGCTGAGTCCTCCCGCGCTGGCTGCCCCCGCCGCC
P G R A L L Y S L S Q P L A S L G S
CCCGGCCGCGCGCTGCTCTACAGCCTCAGCCAGCCGCTGGCCTCTCTCGGCAGGTCAGGGGC
Alteration of tal-1 and Human T Cell Leukemiaotide probes representing tal-1 cDNA sequences. These studies
revealed that transcribed sequences of tal-1 are derived from
at least four exons (provisionally designated la, Ib, 11, and
III), the genomic positions and nucleotide sequences ofwhich
are illustrated in Fig. 3. The distinct tal-1 transcripts are ap-
parently derived as a consequence of alternative RNA splicing,
since one species (designated type A mRNA) includes exons
Ia, 11, and III, whilethe other (type B mRNA)contains exons
Ib, II, and III. The effect of t(1;14)(p34;gll) translocation
on the expression of type B mRNA transcripts cannot be
evaluated until its transcription startsite is defined. Neverthe-
less, since the t(1;14)(p34;gll) mbr lies downstream ofexon
la, it is clear that translocated alleles of tal-1 are usually trun-
cated so as to preclude normal expression of type A tran-
scripts (Fig. 3).
Sequences encoding the tal-1 HLH domain are located
within exon III at a position x+11 kb downstream of the
t(1;14)(p34;gll) mbr (Fig. 3). The cDNA sequences deter-
mined for type A and type B transcripts do not extend
sufficiently 5' to include the initiator codons ofprotein syn-
thesis (1, 6). Hence, known sequences within the upstream
exons (la, lb, and II) also have amino acid coding potential.
The existence of coding sequences within exon la is espe-
cially significant because this exon is removed from the tal-1
locus as a consequence of t(1;14)(p34;gll) translocation. .
Moreover, the 90-kb deletion engendered by tah recombi-
nation also results in the removal ofexon la (14). Consequently,
the tat-1 gene alterations associated with TALL, whether they
arise by t(1;14)(p34;gll) translocation or tald recombination,
are structurally analogous lesions that eliminate normal ex-
pression of the type A mRNA protein product.
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